Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 26:17:211-218.
doi: 10.2147/CCID.S432422. eCollection 2024.

The Association of Telangiectasias with Other Peripheral Vascular Lesions of Systemic Sclerosis

Carmen Bobeica #  1 , Elena Niculet #  2   3 , Carmina Liana Musat #  2 , Lina Iancu  4 , Mihaela Craescu  2   3 , Andreea Mioara Luca  5 , Bogdan Ioan Stefanescu  6 , Emma Gheorghe  7 , Mihaela Debita  8 , Claudiu-Ionut Vasile  8 , Gabriela Balan  8   9   10 , Camelia Busila  8 , Alin Laurentiu Tatu  3   8   11
Affiliations

The Association of Telangiectasias with Other Peripheral Vascular Lesions of Systemic Sclerosis

Carmen Bobeica et al. Clin Cosmet Investig Dermatol. .

Abstract

Purpose: Systemic sclerosis (SSc) is a relatively rare collagenosis manifested as microvasculopathy, excessive cutaneous and visceral fibrosis in a background of autoimmune alteration. Autoimmune vasculopathy in SSc occurs early and begins with endothelial cell activation followed by blood vessel intimal proliferation in a context of defective angiogenesis. The alteration of peripheral micro and macrocirculation in SSc is evident through vascular lesions, such as Raynaud's phenomenon, telangiectasias, acrocyanosis, digital ulcers, gangrene, peripheral pulse deficiency. Our paper details the results of the study on the association between telangiectasias and other types of immune-mediated peripheral vascular lesions that can be identified in SSc. The presence of these peripheral vascular lesions can provide information about the magnitude of the peripheral vasculopathy.

Patients and methods: A total of 37 patients diagnosed with SSc, recruited from a university clinic in Bucharest between February 2019 and March 2020, were enrolled in an observational study. We evaluated the presence of telangiectasias, as a stigma of autoimmune microvasculopathy, and their association with other immune-mediated peripheral vascular lesions that may be present in SSc.

Results: The presence of telangiectasias was identified in the absence, but especially in the presence of acrocyanosis and digital ulcerations, and patients with peripheral pulse deficiency almost always had telangiectasias. Less than a quarter of the patients with digital ulcers progressed unfavorably to gangrene, and only one required amputation, telangiectasias being present not only in the patient with amputation but in all patients with gangrene.

Conclusion: We appreciate that telangiectasias may be the clinical expression of peripheral vasculopathy characteristic of SSc, they can often be present in association with other peripheral vascular lesions and may represent a valuable indicator for the gangrene risk of digital ulcerations in SSc.

Keywords: acrocianosis; digital ulcers; phenomenon Raynaud’s; systemic sclerosis; telangiectasias; vascular lesions.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Waszczykowska A, Goś R, Waszczykowska E, Dziankowska-Bartkowiak B, Podgórski M, Jurowski P. The role of angiogenesis factors in the formation of vascular changes in scleroderma by assessment of the concentrations of VEGF and sVEGFR2 in blood serum and tear fluid. Mediators Inflamm. 2020;2020:7649480. doi:10.1155/2020/7649480 - DOI - PMC - PubMed
    1. Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015;37(5):489–500. doi:10.1007/s00281-015-0505-5 - DOI - PubMed
    1. Ruaro B, Smith V, Sulli A, et al. Innovations in the assessment of primary and secondary Raynaud’s phenomenon. Front Pharmacol. 2019;10:360. doi:10.3389/fphar.2019.00360 - DOI - PMC - PubMed
    1. Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022;38(3):187–195. doi:10.1002/kjm2.12505 - DOI - PMC - PubMed
    1. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology. 1999;38(7):612–617. doi:10.1093/rheumatology/38.7.612 - DOI - PubMed